English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduResearchers at the Icahn School of Medicine at Mount Sinai have shed valuable light on the complex mechanisms by which a class of psychedelic drugs binds to and activates serotonin receptors to produce potential therapeutic effects in patients with neuropsychiatric disorders such as depression and anxiety.
Tag: psychedelics
Benefits of psychedelics in obsessive-compulsive disorder: in search of evidence
Intrusive thoughts, involuntary repetition of undesirable gestures and behaviors combined with high anxiety… Obsessive-compulsive disorder (OCD), a disabling condition, affects around 2% of the population, regardless of age.
Psilocybin – a promising therapy for treatment-resistant depression?
A growing body of evidence suggests that psychedelic drugs may be useful in treating various mental health conditions. However, many challenges remain in defining their clinical benefits and overcoming the complex regulatory obstacles to their use.
Reduced frequency & intensity of migraine attacks after single dose of psilocybin
Psilocybin – the active ingredient in psychedelic mushrooms – shows promise for the transitional treatment of episodic migraines in early clinical trials, according to a review from Yale School of Medicine’s Emmanuelle Schindler, M.D., Ph.D. In the first and only…
The Science of Consciousness – 2023 Conference
Over 500 scientists, philosophers, scholars, artists will gather in Taormina Sicily and engage in discussions to try to get as close as possible to the question regarding the nature of consciousness.
Collaborative and creative policies needed to maximize psychedelics’ therapeutic potential
Research supports the promise of psychedelics in treating conditions like depression and post-traumatic stress disorder, but the future regulatory landscape for these drugs remains unclear. Experts from Baylor College of Medicine, the University of Pennsylvania, American University and Harvard Law School call for creativity and collaboration at the federal and state levels in developing policies for the use and oversight of psychedelics and a commitment to developing a strong evidence base for efficacy and safety.
Scientists Reveal Potential Role of Genetic Variants on Psychedelics’ Therapeutic Effects
UNC School of Medicine researchers report that common genetic variations in one serotonin receptor could be a reason why people with psychiatric conditions, such as depression, respond differently to psychedelic treatments.
People respond differently to psychedelic drugs — genetics could be the reason
Psychedelic drugs have shown benefits as treatments for cluster headaches, anxiety and depression in clinical studies, but not for everyone. Now, in ACS Chemical Neuroscience, researchers report that one reason could be common genetic variations in one serotonin receptor.
Mount Sinai’s Center for Psychedelic Psychotherapy and Trauma Research Receives $5 Million Grant From The Bob & Renee Parsons Foundation
Funds will support cutting-edge MDMA-assisted therapy for PTSD
Research News Tip Sheet: Story Ideas From Johns Hopkins
During the COVID-19 pandemic, Johns Hopkins Medicine Media Relations is focused on disseminating current, accurate and useful information to the public via the media. As part of that effort, we are distributing our “COVID-19 Tip Sheet: Story Ideas from Johns Hopkins” every Tuesday throughout the duration of the outbreak.